NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Hoffmann-La Roche (Roche) back to previous page show list

Hoffmann-La Roche (Roche)

»
address: Roche Products Ltd Hexagon Place
6 Falcon Way
Welwyn Garden City
Hertfordshire
AL7 1TW
contact: Tel: 01707 366000
Fax: 01707 338297
Email: welwyn.corporate_affairs@roche.com
key person: Corporate Executive Committee
Chief Executive Officer
Dr Franz B. Humer (1946)
Pharmaceuticals Division, CEO Division Roche Pharmaceuticals
William M. Burns (1947)
Diagnostics Division, CEO Division Roche Diagnostic

trunover in millions USD: 34483
R & D turnover in millions USD: 5404
NET profit: 7505
year of financial results: 2006
employees: 74372

active in China: YES
partner in China: Roche (China) Ltd.
Floor 2-3, Building 2
1100 Long Dong Avenue
Pudong New Area
CN-201203 Shanghai
PR CHINA
Tel +86-21-5080 1888
Fax +86-21-5080 1800
Major local websitewww.roche.com.cn
www.roc

SFDA approved: NO

Approvals:
GLP: YES
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: YES
Active Pharmaceutical: YES
R&D: YES
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: YES
Work Up (pilot to production): YES
Analysis: YES
Quality Control: YES
Stability: YES
Batch Release: YES

Clinical trials:
Run/Manage: NO
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: YES
 

Roche is one of the world’s leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market and is the leading supplier of pharmaceuticals for cancer and a leader in virology and transplantation. As a supplier of products and services for the prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche employs roughly 74,000 people in 150 countries. The Group has alliances and research and development agreements with numerous partners, including majority ownership interests in Genentech and Chugai.

Roche's pioneering approach to healthcare innovation enables us to deliver significant benefits to patients as well as to healthcare providers and systems. In our vision of the future, therapies will be available for many of today's untreatable diseases, it will be possible to optimize drug efficacy and safety, and effective strategies will be in place for preventing disease. Early diagnosis and improved new treatments will significantly reduce the need for expensive surgical operations and long hospital stays.

While this vision is an aspiration for the future, Roche has begun pioneering the path, with a wide range of products and services available to:

  • determine disease predisposition
  • provide health information that can be acted upon to prevent or delay the onset of illness
  • diagnose disease
  • treat numerous diseases and conditions
  • monitor the progress of therapy

 Roche in China

The Roche Group has four companies and a research center in China, representing its core pharmaceuticals and diagnostics businesses. Located in Hong Kong and Shanghai, they employ some 1300 people. In collaboration with the two Chinese National Human Genome Centers, Roche is conducting genetic epidemiology studies to identify genetic predispositions to diseases such as diabetes or Alzheimer’s.

 

 


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.